Skip to main content
. 2015 Dec 30;10(12):e0145380. doi: 10.1371/journal.pone.0145380

Fig 3. Susceptibility of empiric anti-TB treatment (a)1 and hypothetical susceptibility presuming RHZE had been initiated (b)2.

Fig 3

1The number of active drugs for a patient was calculated based on initial anti-TB therapy and DST results within the first month of therapy (available for 585/1396 patients). 2The number of active drugs in the initial anti-TB treatment regimen, assuming RHZE had been initiated in all subjects (available for 585/1396 patients).